## Edgar Filing: Or Yat Sun - Form 4

Or Yat Sun Form 4								
November 20, 2018								
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMIS Washington, D.C. 20549				E COMMISSION		PPROVAL 3235-0287 January 31,		
if no longer		BENEFI RITIES	CIAL O	WNERSHIP OF	Expires: Estimated burden hou response	2005 average burs per		
obligations	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							
(Print or Type Responses)								
1. Name and Address of R Or Yat Sun	2. Issuer Name <b>and</b> Ticker or Trading Symbol ENANTA PHARMACEUTICALS			5. Relationship of Reporting Person(s) to Issuer				
		INC [ENTA]			(Che	ck all applicabl	e)	
(Last) (First) C/O ENANTA PHARMACEUTICA ARSENAL STREET	(Middle) LS, INC., 500	3. Date of Earliest 7 (Month/Day/Year) 11/16/2018	ransaction		Director X Officer (giv below) S		% Owner ler (specify	
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
WATERTOWN, MA	02472				Form filed by Person	More than One R	eporting	
(City) (State)	(Zip)	Table I - Non-	Derivative S	Securities	Acquired, Disposed o	of, or Beneficia	lly Owned	
	on Date 2A. Deem //Year) Execution any (Month/Da	Date, if Transactio Code ay/Year) (Instr. 8)	Disposed of (Instr. 3, 4	A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Report on a sepa	arate line for each cl	ass of securities bene	ficially own	ed directly	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: Or Yat Sun - Form 4

	1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
	Stock Option (right to buy)	\$ 81.2	11/16/2018		А	20,000	<u>(1)</u>	11/16/2028	Common Stock	20,000	
	Repor	ting O	wners								
	<b>Reporting Owner Name / Address</b> Direct				<b>Relationships</b> r 10% Owner Officer Other						
Or Yat Sun				1070 0 0	iler officer	· · · ·					

Sr. VP & CSO

C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN, MA 02472

## Signatures

/s/ Nathaniel S. Gardiner as attorney-in-fact	11/20/2018			
<u>**Signature of Reporting Person</u>	Date			

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (1) (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole

share equivalent is accumulated) over four years from the date of grant (November 16, 2018).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.